---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-090715"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2025-09-23T23:59:59+00:00"
generated_at: "2026-05-17T05:53:19.743035+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InMed reports FY2025 net loss of $8.2M; BayMedica revenue up 8% to $4.9M

## Summary
- Net loss $8.2M vs $7.7M prior year; diluted EPS ($8.36) vs ($20.14) on higher share count.
- Cash $11.1M, up from $6.6M; expected to fund operations into Q4 2026.
- BayMedica segment sales $4.9M (+8% YoY); gross profit rose to $1.7M from $1.1M.
- INM-901 Alzheimer's candidate: significant neuroinflammation reductions and oral bioavailability data.
- INM-089 dry AMD program selected intravitreal formulation; doses up to 10x safety margin.

## SEC filing metadata
- accession: 0001213900-25-090715
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2025-09-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390025090715/0001213900-25-090715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390025090715/ea0258458-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-090715
- JSON: https://secwatch.observer/filing/0001213900-25-090715.json
- Plain text: https://secwatch.observer/filing/0001213900-25-090715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.